Will EKSO's Q1 2025 forecast beat expectations?

**Ekso Bionics' Q1 2025 forecast is unlikely to beat expectations based on the available data and analysis.** Here's a detailed assessment: 1. **Revenue Projection**: The estimated revenue for Q1 2025 is $4.75 million. This is slightly below the revenue of $5.1 million reported for Q4 2024. The discrepancy suggests that the forecast might be conservative, but it also indicates a potential shortfall compared to the recent past. 2. **Earnings Projection**: The estimated EPS for Q1 2025 is -$0.11. This is worse than the EPS of -$0.14 reported for Q4 2024. The trend indicates a potential deterioration in profitability, which could lead to earnings missing expectations. 3. **Historical Performance**: Ekso Bionics has experienced a decline in stock price and a decrease in market capitalization, with the stock down over 73% in the past year. This historical performance suggests underlying challenges that could impact Q1 2025 results. 4. **Analyst Expectations**: Analysts have mixed expectations for Ekso Bionics, with a recent analysis showing a decline in revenue and an increase in per-share losses expected for 2025. This aligns with the cautious outlook for Q1 2025. 5. **Market Sentiment**: The company's stock has fallen significantly, reflecting investor concerns. This sentiment could persist if Q1 2025 results do not meet expectations. In conclusion, given the lower revenue projection, the worsening EPS trend, historical stock performance, analyst expectations, and current market sentiment, Ekso Bionics' Q1 2025 forecast is unlikely to exceed market expectations.